Screener
Janux Therapeutics JANX Deferred Tax Assets and Other Non-Current Assets
Deferred Tax Assets and Other Non-Current Assets at other companies
Other financials
Where this comes from
Reported directly by Janux Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OtherAssetsNoncurrent.
The source filing: Janux Therapeutics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:18 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-338078
| Assets | June 30,2026 / (unaudited) | December 31,2025 |
|---|---|---|
| Restricted cash | 816 | 816 |
| Property and equipment, net | 3,260 | 3,852 |
| Operating lease right-of-use assets | 17,327 | 18,402 |
| Other long-term assets | 2,913 | 2,608 |
| Total assets | $1,007,653 | $1,001,565 |
| Liabilities and Stockholders’ Equity | ||
| Current liabilities: | ||
| Accounts payable | $3,017 | $4,971 |
Item 1. Financial Statements.
FAQ
- What is Janux Therapeutics's deferred tax assets and other non-current assets?
- Janux Therapeutics (JANX) reported deferred tax assets and other non-current assets of $2.91M in Q2 2026.
- How has Janux Therapeutics's deferred tax assets and other non-current assets changed year-over-year?
- Janux Therapeutics's deferred tax assets and other non-current assets increased by 8.2% year-over-year, from $2.69M to $2.91M.
- What does deferred tax assets and other non-current assets mean?
- Combined balance of non-current deferred tax assets and other miscellaneous non-current assets.
Ask your AI about Janux Therapeutics's deferred tax assets and other non-current assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude